Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European Medicines Agency: A multicenter observational study

1. Morell, L.
2. Carrascosa, J.M.
3. Ferrándiz, C.
4. García-Bustinduy, M.
5. Fonseca, E.
6. Carretero, G.
7. Daudén, E.
8. Marrón, S.E.
9. López-Estebaranz, J.L.
10. Ferrán, M.
11. Sánchez-Regaña, M.
12. Muñoz-Santos, C.
13. Belinchón, I.
14. Puig, L.